BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MDS Inc. (MDZ) Completes Divestiture of MDS Analytical Technologies


2/1/2010 8:36:57 AM

TORONTO, Feb. 1 /PRNewswire-FirstCall/ - MDS Inc. , a leading provider of products and services to the global life sciences markets, today announced that it has completed the divestiture of its MDS Analytical Technologies business to Danaher Corporation for $650 million in cash.

"The divestiture of the MDS Analytical Technologies business marks a significant milestone in the Company's repositioning strategy and enables a substantial return of proceeds from the sale to shareholders," said Steve West, Chief Executive Officer, MDS Inc.

Proceeds from the Sale

MDS intends to return approximately $400 million to $450 million of the sale proceeds to shareholders by way of a share buyback through a Substantial Issuer Bid. The Company currently expects to initiate a Substantial Issuer Bid within the next 30 days.

Changes to Capital Structure

Concurrent with the closing of the sale, MDS has initiated actions to terminate its undrawn C$500 million revolving credit facility and to retire all outstanding Senior Unsecured Notes at a cost of approximately $223 million including principal, interest and make whole payments by February 3, 2010. The Company also deposited approximately $20 million in cash collateral to support existing letters of credit.

MDS Strategic Repositioning

Background materials pertaining to the new strategic direction for MDS Inc. can be found on MDS Inc.'s Website at http://www.mdsinc.com/strategic_repositioning_of_mds/index.asp.

About MDS

MDS Inc. is a global life sciences company that provides market-leading products and services that customers need for the development of drugs and the diagnosis and treatment of disease. MDS Inc. is a leading global provider of innovative technologies for use in medical imaging and radiotherapeutics, sterilization, and pharmaceutical contract research. MDS has more than 2,400 highly skilled people in nine countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

CONTACT: MEDIA: Janet Ko, (905) 267-4226, janet.ko@mdsinc.com; INVESTORS:
Catherine Love, (905) 267-4230, catherine.love@mdsinc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES